The Bone, Exercise, Alendronate, and Caloric Restriction (BEACON) Trial

Primary Objective

The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight

Is This Study For You?

Let's Get Started!

Description

The purpose of this research study is to identify strategies that minimize bone loss that occurs when older adults lose weight. Your participation in this research study will involve a groupmediated weight loss intervention and may involve resistance training and/or 70 mg of weekly oral alendronate or placebo for 52 weeks. Alendronate is a medication that prevents bone breakdown and has been approved by the US Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in older men and women. In this study, a drug will be compared to a placebo. A placebo is a substance is a substance that is not thought to have any effect on your disease or condition. In this study you will either receive the active study medication, or placebo which is not active. Placebos are used in research studies to see if the drug being studied really does have an effect.

Details
Age
Adult
Eligibility
You may be eligible if you are: At least 60 years of age and would benefit from a weight loss program Living with low bone mass (known as osteopenia - testing for this will be provided by the study) Willing to travel to the University of Colorado Anschutz Medical Campus up to 3 days a week for 1 year Not currently using insulin or osteoporosis medication
Locations

Outpatient CTRC

Principal Investigator
Photograph of Sarah Wherry

Sarah Wherry

Study ID

Protocol Number: 22-2041

More information available at ClinicalTrials.gov: NCT05764733

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers